Biolargo Inc (BLGO) Financial Statements (2024 and earlier)

Company Profile

Business Address 14921 CHESTNUT ST.
WESTMINSTER, CA 92683
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 28 - Chemicals And Allied Products (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,5391,851962716655655
Cash and cash equivalents3,5391,851962716655655
Receivables2,6121,064513484355257
Inventory, net of allowances, customer advances and progress billings1531202412771626
Inventory1531202412771626
Other undisclosed current assets5811885283917
Total current assets:6,3623,1531,8011,5051,065955
Noncurrent Assets
Operating lease, right-of-use asset1,092867453341411
Property, plant and equipment662287616095126
Long-term investments and receivables19334863  
Long-term investments19334863  
Intangible assets, net (including goodwill)    2,1501,8931,893
Intangible assets, net (excluding goodwill)    2,1501,8931,893
Prepaid expense  394591788  
Other noncurrent assets7012469353535
Other undisclosed noncurrent assets     122176
Total noncurrent assets:1,8431,7051,2223,4372,5562,230
TOTAL ASSETS:8,2054,8583,0234,9423,6213,185
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,488940559513602501
Interest and dividends payable2542125122
Employee-related liabilities1841561277
Accounts payable1,212717350315465302
Accrued liabilities276223    
Deferred revenue30317894835
Debt661003141,2065,064 
Other undisclosed current liabilities8535194121,777(1,347)1,990
Total current liabilities:2,7101,5761,3743,5444,3542,491
Noncurrent Liabilities
Long-term debt and lease obligation2892375297339861,292
Long-term debt, excluding current maturities2892371805077001,292
Liabilities, other than long-term debt1,004773 900  
Financial instruments subject to mandatory redemption, settlement terms, share value, amount    900  
Operating lease, liability1,004773349226286
Other undisclosed noncurrent liabilities  261(162) 461525
Total noncurrent liabilities:1,2931,2717161,6331,4471,817
Total liabilities:4,0032,8472,0905,1775,8014,308
Equity
Equity, attributable to parent6,8444,8784,6533,858(2,153)(1,496)
Common stock19618617115111195
Additional paid in capital154,023148,435143,718135,849121,327110,222
Accumulated other comprehensive loss(277)(149)(115)(101)(99)(90)
Accumulated deficit(147,098)(143,594)(139,121)(132,041)(123,492)(111,723)
Equity, attributable to noncontrolling interest(2,642)(2,867)(3,720)(4,093)(27)373
Total equity:4,2022,011933(235)(2,180)(1,123)
TOTAL LIABILITIES AND EQUITY:8,2054,8583,0234,9423,6213,185

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues12,2305,8842,5312,4321,8611,364
Cost of revenue
(Cost of Goods and Services Sold)
(6,076)(3,027)(1,428)(1,204)(945)(743)
Other undisclosed gross profit      
Gross profit:6,1542,8571,1031,228916621
Operating expenses(10,734)(8,247)(7,539)(8,811)(7,612)(7,033)
Operating loss:(4,580)(5,390)(6,436)(7,583)(6,696)(6,412)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(68)258(458)(2,117)(4,744)(4,284)
Interest and debt expense(91)(53)(234)(2,365)(1,029)(276)
Loss from continuing operations before equity method investments, income taxes:(4,739)(5,185)(7,128)(12,065)(12,469)(10,972)
Loss from equity method investments   (15)(37)  
Loss from continuing operations:(4,739)(5,185)(7,143)(12,102)(12,469)(10,972)
Loss before gain (loss) on sale of properties:(7,143)(12,102)(12,469)(10,972)
Other undisclosed net income91532492,4021,029276
Net loss:(4,648)(5,132)(6,894)(9,700)(11,440)(10,696)
Net income attributable to noncontrolling interest1,144659    
Net loss attributable to parent:(3,504)(4,473)(6,894)(9,700)(11,440)(10,696)
Other undisclosed net income (loss) available to common stockholders, basic   (186)1,268750475
Net loss available to common stockholders, diluted:(3,504)(4,473)(7,080)(8,432)(10,690)(10,221)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(4,648)(5,132)(6,894)(9,700)(11,440)(10,696)
Other undisclosed comprehensive loss(128)(34)(14)(2)(9)(28)
Comprehensive loss:(4,776)(5,166)(6,908)(9,702)(11,449)(10,724)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest1,144659(186)1,268750475
Comprehensive loss, net of tax, attributable to parent:(3,632)(4,507)(7,094)(8,434)(10,699)(10,249)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: